Skip to Main Content

Paper Details

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Blood Adv
95
2021
Author NameAffiliation
Martin S TallmanMemorial Sloan Kettering Cancer Center
Martin S TallmanWeill Cornell Medical College
  • 1 - 2

Datasets

Release 1.2